Objective Following the licensure of 23-valent pneumococcal polysaccharide vaccine
(23vPPV) in 1989, a risk-group–only immunization policy was implemented in 1992 in …

Within Australia, Victoria is the only jurisdiction where the 23-valent polysaccharide
pneumococcal vaccine (23vPPV) has been publicly funded for the elderly (aged≥ 65 …

Objective: To evaluate the impact and effectiveness of the 23‐valent polysaccharide
pneumococcal vaccine (23vPPV) in≥ 65‐year‐old Australians in the context of concurrent 7 …

The 23-valent pneumococcal polysaccharide vaccine (PPV) has been available for a
number of years and is recommended for high-risk categories. Relatively immunocompetent …

In 1998, a publicly funded pneumococcal vaccine program was introduced for persons
aged≥ 65 years in Victoria, Australia. In 2000, vaccine coverage over the previous 5 years …

A 23-valent polysaccharide pneumococcal vaccine (PPV) has been available in the UK for
more than 20 years and is currently recommended for use in high-risk groups (HRG) of 2+ …

Background Pneumococcal polysaccharide vaccine (PPV) is recommended for all adults 65
years of age and older and for younger adults with high-risk conditions. While data from …

Although pneumococcal vaccine is recommended by the National Health and Medical
Research Council and is cost‐effective in preventing invasive pneumococcal disease, it is …

Background Pneumococcal disease in older adults in the United Kingdom is rising despite
immunisation. A key gap in the literature is the clinical effectiveness of revaccination with the …

In 2003 the existing 23-valent pneumococcal vaccine (PPV23) programme for high risk
groups was extended to include all≥ 65 year olds in England and Wales, starting with≥ 80 …